Because DEX is a wide-spectrum anti-inflammatory drug that may cause severe side effects, more specific, CXCL13/CXCR5-targeting antibodies or small molecules should be developed to combat lung cancer, the leading cause of cancer-related mortality accounting for 1.59 million deaths worldwide in 2012 (WHO, 2012). Here, CXCR5 is linked to lung carcinoma.